Latest News of VRNA
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs
By Yahoo! Finance |
2 weeks ago
Over 5,000 unique patients have been prescribed Ohtuvayre, with increasing refills and patient adds. Prescriber trends show a broad range of therapy combinations. Infrastructure for patient access is ...
Insider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA)
By Yahoo! Finance |
2 months ago
On September 11, 2024, Verona Pharma PLC's CFO, Mark Hahn, sold 600,000 shares, now owning 14,339,688 shares. The biopharmaceutical company focuses on respiratory disease therapies....
Verona Pharma PLC (VRNA) CEO David Zaccardelli Sells 600,000 Shares
By Yahoo! Finance |
2 months ago
David Zaccardelli, CEO of Verona Pharma PLC, recently sold 600,000 shares of the company, bringing his total ownership to 15,250,704 shares. The company focuses on respiratory disease therapies....
-
Insider Sale: CFO Mark Hahn Sells 400,000 Shares of Verona Pharma PLC (VRNA)
By Yahoo! Finance | 3 months agoThe CFO of Verona Pharma PLC sold 400,000 shares, bringing total ownership to 14,939,688. The company focuses on respiratory disease treatments. The recent insider sale aligns with a trend of more sal...
-
Verona Pharma plc's (NASDAQ:VRNA) Path To Profitability
By Yahoo! Finance | 3 months agoVerona Pharma is a biopharmaceutical company focusing on respiratory diseases. Analysts predict breakeven by 2025, expecting a profit of US$60m in 2026 with a 59% growth rate. The company's low debt a...